Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice Mitchell S. von Itzstein Yuqiu Yang Yiqing Wang David Hsiehchen Thomas Y. Sheffield Farjana Fattah Vinita Popat Murtaza Ahmed Jade Homsi Jonathan E. Dowell Sawsan Rashdan Jay Lohrey Hans J. Hammers Randall S. Hughes Tao Wang Yang Xie David E. Gerber Background

A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of treatment initiation, thereby providing information prior to efficacy assessment. Although immune checkpoint inhibitor (ICI)-associated immune-related adverse events (irAE) have been associated with therapeutic benefit, irAE may have delayed and highly variable onset. To determine whether ICI efficacy and irAE could serve as clinically useful biomarkers for predicting each other, we determined the temporal relationship between initial efficacy assessment and irAE onset in a diverse population treated with ICI.
Methods

Using two-sided Fisher exact and Cochran-Armitage tests, we determined the relative timing of initial efficacy assessment and irAE occurrence in a cohort of 155 ICI-treated patients (median age 68 years, 40% women).
Results

Initial efficacy assessment was performed a median of 50 days [interquartile range (IQR) 39-59 days] after ICI initiation; median time to any irAE was 77 days (IQR 28-145 days) after ICI initiation. Median time to first irAE was 42 days (IQR 20-88 days). Overall, 58% of any irAE and 47% of first irAE occurred after initial efficacy assessment. For clinically significant (grade ≥2) irAE, 60% of any and 53% of first occurred after initial efficacy assessment. The likelihood of any future irAE did not differ according to response (45% for complete or partial response vs. 47% for other cases; P =1). In landmark analyses controlling for clinical and toxicity follow-up, patients demonstrating greater tumor shrinkage at initial efficacy assessment were more likely to develop future grade ≥2 ( P =0.05) and multi-organ ( P =0.02) irAE.
Conclusions

In contrast to that seen with chemotherapy and molecularly targeted therapies, the temporal relationship between ICI efficacy and toxicity is complex and bidirectional. In practice, neither parameter can be routinely relied on as a clinical biomarker to predict the other.
4 16 2024 1351739 10.3389/fimmu.2024.1351739 1 10.3389/crossmark-policy frontiersin.org true National Institute of Allergy and Infectious Diseases http://dx.doi.org/10.13039/100000060 National Institutes of Health http://dx.doi.org/10.13039/100000002 American Cancer Society http://dx.doi.org/10.13039/100000048 https://creativecommons.org/licenses/by/4.0/ 10.3389/fimmu.2024.1351739 https://www.frontiersin.org/articles/10.3389/fimmu.2024.1351739/full https://www.frontiersin.org/articles/10.3389/fimmu.2024.1351739/full Cancer Chemother Pharmacol Shitara 68 2011 Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with Malignant disease undergoing chemotherapy 10.1007/s00280-010-1487-6 Eur J Cancer Shitara 45 2009 Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX 10.1016/j.ejca.2009.01.019 Br J Cancer Saarto 75 1997 Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer 10.1038/bjc.1997.49 Lancet Oncol Di Maio 6 2005 Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials 10.1016/S1470-2045(05)70255-2 Eur J Cancer Sehouli 51 2015 Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients 10.1016/j.ejca.2015.01.008 J Clin Oncol Moore 25 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group 10.1200/JCO.2006.07.9525 Ann Oncol Holch 31 2020 Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) 10.1016/j.annonc.2019.10.001 Int J Radiat Oncol Biol Phys Bar-Ad 95 2016 Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG experience 10.1016/j.ijrobp.2016.03.011 N Engl J Med Shepherd 353 2005 Erlotinib in previously treated non-small-cell lung cancer 10.1056/NEJMoa050753 JAMA Kris 290 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial 10.1001/jama.290.16.2149 J Clin Oncol Dahlberg 28 2010 Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 10.1200/JCO.2009.25.4482 J Natl Cancer Inst Rini 103 2011 Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib 10.1093/jnci/djr128 J Immunother Cancer Das 7 306 2019 Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors 10.1186/s40425-019-0805-8 Eur J Cancer Rogado 109 2019 Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients 10.1016/j.ejca.2018.10.014 Lung Cancer Sato 115 2018 Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab 10.1016/j.lungcan.2017.11.019 J Clin Oncol Maher 37 2019 Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody 10.1200/JCO.19.00318 J Clin Oncol Ribas 23 2005 Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 10.1200/JCO.2005.01.109 Clin Cancer Res Downey 13 2007 Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade 10.1158/1078-0432.CCR-07-0187 Oncoimmunology Hsiehchen 11 2017162 2022 Association between immune-related adverse event timing and treatment outcomes 10.1080/2162402X.2021.2017162 P T Moore 41 2016 Drug-induced neutropenia: A focus on rituximab-induced late-onset neutropenia J Clin Oncol Chan 17 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer 10.1200/JCO.1999.17.8.2341 BMC Cancer Chen 17 242 2017 Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients 10.1186/s12885-017-3240-6 Oncotarget Chen 8 2017 Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine/gemcitabine-based chemotherapy 10.18632/oncotarget.v8i39 J Clin Oncol Hidalgo 19 2001 Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid Malignancies 10.1200/JCO.2001.19.13.3267 Clin Lung Cancer Perez-Soler S7 2006 Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer 10.3816/CLC.2006.s.008 N Engl J Med Postow 378 2018 Immune-related adverse events associated with immune checkpoint blockade 10.1056/NEJMra1703481 Eur J Cancer Ghisoni 149 2021 Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 10.1016/j.ejca.2021.03.010 Nat Rev Dis Primers Ramos-Casals 6 38 2020 Immune-related adverse events of checkpoint inhibitors 10.1038/s41572-020-0160-6 J Immunother Cancer Ostmeyer 11 2023 T-cell tolerant fraction as a predictor of immune-related adverse events 10.1136/jitc-2022-006437 Br J Cancer Khan 120 2018 Immune dysregulation in cancer patients developing immune-related adverse events 10.1038/s41416-018-0155-1 JAMA Netw Open Hsiehchen 2 e1911519 2019 Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors 10.1001/jamanetworkopen.2019.11519 Nat Rev Cancer Topalian 16 2016 Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy 10.1038/nrc.2016.36 J Clin Oncol Overman 36 2018 Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer 10.1200/JCO.2017.76.9901 Nat Rev Cancer Yarchoan 17 2017 Targeting neoantigens to augment antitumour immunity 10.1038/nrc.2016.154 N Engl J Med Yarchoan 377 2017 Tumor mutational burden and response rate to PD-1 inhibition 10.1056/NEJMc1713444 Science Rizvi 348 2015 Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer 10.1126/science.aaa1348 J Immunother Cancer Ahmed 9 2021 Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors 10.1136/jitc-2021-002349 JAMA Oncol Pinato 5 2019 Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer 10.1001/jamaoncol.2019.2785 Clin Chem von Itzstein 66 2020 Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis 10.1093/clinchem/hvaa081 J Immunother Cancer Ghosh 10 2022 Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition 10.1136/jitc-2021-004008 Cell Rep Med Bukhari 4 100868 2023 Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors 10.1016/j.xcrm.2022.100868 JAMA Oncol Khan 2 2016 Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options 10.1001/jamaoncol.2016.2238 Cancer J von Itzstein 26 2020 Immunotherapy use in patients with lung cancer and comorbidities 10.1097/PPO.0000000000000484 Eur J Cancer Brahmer 50 2014 Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503) 10.1016/j.ejca.2013.10.006 Br J Cancer Shitara 110 2014 Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer 10.1038/bjc.2013.726 Med Oncol Drooger 32 113 2015 Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study 10.1007/s12032-015-0550-x J Immunother Cancer Brahmer 9 2021 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 10.1136/jitc-2021-002435 N Engl J Med Kantoff 363 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer 10.1056/NEJMoa1001294 Lancet Oncol Seymour 18 2017 iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics 10.1016/S1470-2045(17)30074-8 Ann Oncol Borcoman 30 2019 Novel patterns of response under immunotherapy 10.1093/annonc/mdz003 Oncologist Popat 25 2020 Lack of association between radiographic tumor burden and efficacy of immune checkpoint inhibitors in advanced lung cancer 10.1634/theoncologist.2019-0814 N Engl J Med Brahmer 373 2015 Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer 10.1056/NEJMoa1504627 Cancers (Basel) Petrelli 12 546 2020 Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis 10.3390/cancers12030546 NPJ Precis Oncol Wang 5 82 2021 Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types 10.1038/s41698-021-00223-x DataSheet_1.docx 10.3389/fimmu.2024.1351739.s001 https://www.frontiersin.org/articles/10.3389/fimmu.2024.1351739/supplementary-material/10.3389/fimmu.2024.1351739.s001